Roger Kornberg, Ph.D.

Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board

Dr. Roger Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University. He has been a member of the faculty of Stanford University since 1978. In 2006, Dr. Kornberg was awarded the Nobel Prize in Chemistry in recognition for his studies of the molecular basis of Eukaryotic Transcription, the process by which DNA is copied to RNA. Dr. Kornberg is also the recipient of several awards, including the 2001 Welch Prize, the highest award granted in the field of chemistry in the United States, and the 2002 Leopald Mayer Prize, the highest award granted in the field of biomedical sciences from the French Academy of Sciences.

Steve Rubin

Vice Chairman

Mr. Steve Rubin is Executive Vice President-Administration and a director of OPKO Health, Inc. Previously, he was Senior Vice President and General Counsel of IVAX. Prior to IVAX, Mr. Rubin was Senior Vice President and General Counsel of Telergy Inc. Mr. Rubin holds a B.A. from Tulane University and a J.D. degree from University of Florida.

Phillip Frost, M.D.

Director

Dr. Phillip Frost is the Chairman and CEO of OPKO Health, Inc. (NYSE: OPK). Dr. Frost is the former Chairman of the Board of Teva Pharmaceuticals (NYSE: TEVA). Dr. Frost served as Chairman and CEO of IVAX Corporation from 1987 through that firm’s acquisition by IVAX Corporation in January 2006. He has served on the Board of Regents of the Smithsonian Institution, on the Board of Trustees of the University of Miami, as a Trustee of each of the Scripps Research Institutes, and is a director of numerous other organizations.

Fred Hassan

Director

Mr. Hassan is Chairman of the investment firm Caret Group and a Director of Warburg Pincus LLC, a global private equity firm. From 2003 to 2009 Mr. Hassan served as Chairman and Chief Executive Officer of Schering-Plough and from 2001 to 2003 he was Chairman and Chief Executive Officer of Pharmacia Corporation, a company via the merger of Monsanto Company and Pharmacia & Upjohn, Inc. He joined Pharmacia & Upjohn, Inc. as Chief Executive Officer in 1997. Earlier in his career Mr. Hassan held leadership positions with Wyeth, including serving as Executive Vice President and as a Director from 1995 to 1997, and with Sandoz Pharmaceuticals, including leading its U.S. pharmaceuticals business.

Mr. Hassan is a Director of Precigen, Inc., BridgeBio Pharma and Prometheus Biosciences, Inc. Previously he was a Director of Amgen, Inc. and Time Warner Inc. (now Warner Media, LLC). Over the course of his career, he has served on various other Boards including at Avon Products, Inc. and Bausch & Lomb, which was acquired by Valeant Pharmaceuticals International, Inc.

Mr. Hassan has chaired several prominent pharmaceutical industry organizations including The Pharmaceutical Research and Manufacturers of America (PhRMA) and The International Federation of Pharmaceutical Manufacturers Associations (IFPMA). He received a BS in chemical engineering from the Imperial College of Science and Technology at the University of London and an MBA from Harvard Business School.

Anthony Japour, M.D.

Director

Dr. Anthony Japour is President, CEO and Director of iTolerance, a privately held regenerative medicine company.  He also serves on the Boston Advisory Council for the George Washington School of Business Transformative Leadership during Disruptive Times Certificate Program. From May 2020 to August 2020, he served as CEO of AdvancedDx Biological Laboratories-USA (ABLDx-USA), a virologic diagnostic solutions company, and from February 2016 to April 2020 he was Medical Director of ICON plc, a global provider of outsourced drug development and commercialization solutions and services to the pharmaceutical, biotechnology, medical device and government and public health organizations from. From April 2012 to February 2016, Dr. Japour worked as an internal medicine physician at Elite Health Medical Group in Miami Beach, Florida, where he specialized in infectious diseases. Dr. Japour is also the owner and director of Anthony Japour and Associates, Medical and Scientific Consulting, Inc., a medical and scientific consulting firm he established in November 2006.

Richard C. Pfenniger, Jr.

Director

Mr. Pfenniger is a private investor who served as Interim CEO of Vein Clinics of America, Inc., a privately held company that specializes in the treatment of vein disease, from May 2014 to February 2015, and as Interim CEO of IntegraMed America, Inc., a privately held company that manages outpatient fertility medical centers, from January 2013 to June 2013. He served as CEO and President of Continucare Corporation, a provider of primary care physician and practice management services, from 2003 to 2011, and as Chairman of the Board of Continucare Corporation from 2002 to 2011. Previously, Mr. Pfenniger served as CEO and Vice Chairman of Whitman Education Group, Inc. from 1997 to June 2003. Before that, he served at the IVAX Corporation as COO from 1994 to 1997, and as Senior Vice President-Legal Affairs and General Counsel from 1989 to 1994. He previously was engaged in the private practice of law. Mr. Pfenniger is a director of OPKO Health (Nasdaq: OPK), GP Strategies Corporation (NYSE: GPX) and Asensus Surgical, Inc. (NYSE American: ASXC).